HCPCS Code Q5121: Billing guide for infliximab-axxq (Avsola)

Key Takeaways

HCPCS Code Q5121 describes injection, infliximab-axxq, biosimilar (Avsola), 10 mg – effective July 1, 2020

Q5121 carries a coverage code of C (carrier judgment), meaning Medicare coverage is determined case by case

Avsola (Q5121) is a biosimilar to Remicade (J1745); bill Q5121 – never J1745 – when dispensing Avsola

Pabau’s claims management software helps infusion and rheumatology practices submit Q5121 claims with correct modifiers and documentation

HCPCS Code Q5121: definition and clinical description

HCPCS Code Q5121 describes the injection of infliximab-axxq, a biosimilar biologic marketed under the brand name Avsola, billed per 10 mg unit. The code was added to the HCPCS Level II code set effective July 1, 2020, and remains valid for 2026 claims. Rheumatology practices, infusion centers, and hospital outpatient departments use HCPCS Code Q5121 whenever Avsola is administered by intravenous infusion to a covered patient.

Infliximab-axxq is manufactured by Amgen. It is a monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), reducing systemic inflammation across several autoimmune conditions. Its mechanism of action is identical to the reference biologic infliximab (Remicade, billed under J1745), and the FDA has approved it as a biosimilar on that basis. Getting the code right from the first submission matters: using J1745 instead of Q5121 when you dispense Avsola will result in a payer mismatch and likely a denial. Robust claims management software flags these substitutions before a claim leaves the practice.

Official code properties

The table below summarises the core HCPCS Level II properties for Q5121 as published by CMS.

Approved indications for Avsola (Q5121)

Infliximab-axxq (Avsola) shares the same FDA-approved indications as its reference product, Remicade. Payers evaluate medical necessity against these indications when adjudicating Q5121 claims. Billing outside an approved indication without supporting documentation is a leading cause of denial.

• Rheumatoid arthritis (RA) – used in combination with methotrexate for moderate to severe RA in adults who have had an inadequate response to methotrexate alone
• Crohn’s disease – for reducing signs and symptoms and inducing and maintaining clinical remission in adults and pediatric patients with moderately to severely active disease
• Ulcerative colitis – for inducing and sustaining clinical remission and mucosal healing in adults and pediatric patients with moderately to severely active disease
• Ankylosing spondylitis – for reducing signs and symptoms in adult patients
• Psoriatic arthritis – for reducing signs and symptoms of active disease in adults
• Plaque psoriasis – for treating adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy

Document the specific indication in the patient record before submitting any Q5121 claim. Payers that require prior authorization will review this documentation as part of their medical necessity determination.

HCPCS Code Q5121 chart: related infliximab biosimilar codes

Multiple infliximab biosimilars have their own distinct HCPCS Q-codes. Using the wrong code – even for a clinically interchangeable product – creates a mismatch between what was dispensed and what was billed. The chart below maps each infliximab product to its current code. For context on how biosimilar coding compares to other specialty procedure coding, see our overview of IVF procedure coding and the separate principles involved.

Some payers publish formulary policies that differentiate between preferred and non-preferred biosimilars within this group. BlueCross BlueShield of Michigan, for example, has designated Avsola (Q5121) and Inflectra (Q5103) as preferred infliximab products, while Remicade (J1745) and Renflexis (Q5104) were listed as non-preferred – though formulary status is payer-specific and subject to change, so verify current policy before submitting. For additional context on how related diagnostic coding principles apply to comorbid conditions that may accompany autoimmune disease presentations, see our broader diagnostic code library.

Medicare and Medicaid billing guidelines for HCPCS Code Q5121

Coverage code C (“carrier judgment”) means no automatic nationwide coverage rule applies to HCPCS Code Q5121. Instead, the Medicare Administrative Contractor (MAC) serving your jurisdiction determines whether the service meets medical necessity requirements on a claim-by-claim or local coverage determination (LCD) basis. Practices must submit adequate clinical documentation with every Q5121 claim to support coverage.

Medicare Part B

Avsola administered in a physician’s office, hospital outpatient department, or freestanding infusion center generally falls under Medicare Part B as a physician-administered drug. Reimbursement is typically calculated at the drug’s Average Sales Price (ASP) plus a percentage add-on, in line with CMS Physician Fee Schedule rules. The standard Medicare beneficiary co-insurance for Part B drugs is 20%, though the specific per-unit dollar amount changes with each annual ASP update. Always verify current reimbursement against the live CMS fee schedule before presenting out-of-pocket estimates to patients.

Practices participating in the buy-and-bill model purchase Avsola directly, administer it, and bill Q5121 to Medicare for reimbursement. The alternative is a specialty pharmacy arrangement, where the drug is shipped directly to the patient or the infusion site. Which model a practice uses affects cash flow, inventory risk, and claim submission. Confirm your site-of-service setup before setting up a billing workflow. Our guides on infusion clinic billing best practices cover how these workflows differ across settings.

Medicaid coverage

State Medicaid programs set their own coverage policies for infliximab biosimilars. North Carolina Medicaid, for example, covers infliximab-axxq under the Physician Administered Drug Program (PADP) and requires providers to bill with HCPCS Code Q5121 for IV use. Indiana’s Health Coverage Programs also cover Q5121, with reimbursement capped under that state’s fee schedule. Because every state program sets its own rate and prior authorization rules, you must verify coverage with each Medicaid plan before administering the drug. Practices serving patients in multiple states benefit from dermatology practice management software that centralises payer-specific rules for each patient encounter.

Dosage, units, and calculating the number of units to bill

HCPCS Code Q5121 is billed per 10 mg of infliximab-axxq administered. Most infliximab dosing protocols are weight-based, which means the number of billable units changes with each patient and each dose.

Standard dosing formula

A common induction and maintenance dosage for rheumatoid arthritis is 3 mg/kg IV, repeated at weeks 0, 2, and 6 and then every 8 weeks. For Crohn’s disease, the dose may be 5 mg/kg on the same schedule. Calculate units billed as follows:

1. Multiply the patient’s weight in kg by the prescribed mg/kg dose to get the total dose in mg.
2. Divide the total dose by 10 (since Q5121 is billed per 10 mg).
3. Round to the nearest whole unit in line with your MAC’s rounding policy.
4. Document the weight, dose calculation, and actual vials used in the patient record.

Example: a 70 kg patient prescribed 5 mg/kg receives 350 mg. Billed units = 350 / 10 = 35 units of Q5121.

Wastage from partially used vials may be billed under some payer contracts. Check your specific MAC or commercial plan policy on billing for discarded drugs and use the appropriate modifier where required. Refer to official FDA labeling for complete prescribing information and any weight-based dosing adjustments before administering the drug.

Automate your infusion billing workflow

Pabau helps rheumatology and infusion practices track weight-based dosing calculations, generate correct unit counts for Q5121 claims, and submit with the right modifiers the first time.

Book a demo

Place of service and modifier guidance for Q5121

Where you administer Avsola determines which place of service (POS) code accompanies HCPCS Code Q5121 on the claim. Using the wrong POS triggers automatic edits and can result in lower reimbursement or denial. For broader context on how specialist procedure billing codes work across different clinical settings, see our reference on specialist procedure code billing.

Common place of service codes for Q5121

Modifier usage

Modifier JA (“administered intravenously”) is commonly required when billing biologic drugs administered by IV infusion, including Avsola. Some payers also require JB (“administered other than intravenously”) when a non-IV route is used – but since Q5121 specifies IV infusion, JA should apply in standard administrations. Always confirm modifier requirements with your specific MAC or commercial payer before submitting. Incorrect modifier usage is one of the most common causes of Q5121 denials. Maintaining HIPAA-compliant claim submission practices also means storing the audit trail for modifier selections in the patient record.

Prior authorization and payer-specific requirements for HCPCS Code Q5121

Prior authorization (PA) requirements for Q5121 vary significantly across payers. There is no universal rule. Most commercial plans require PA for biologic infusions, and many apply step therapy protocols that require documentation of failed conventional therapy before approving an infliximab biosimilar. Some plans also require that the prescribing provider obtain PA separately from the infusion facility.

• Commercial insurers – PA almost always required; step therapy documentation is common. Expect to submit clinical notes, lab results, and prior treatment history.
• Medicare – PA is not required by CMS for most Part B drugs, but local coverage determinations from your MAC may impose documentation requirements. Check your MAC’s LCD for infliximab biosimilars.
• Medicaid – PA requirements vary by state. Some state programs require prior biosimilar trial; others accept physician attestation of medical necessity.
• UnitedHealthcare – publishes a Commercial Medical Benefit Drug Policy that specifies maximum dosage and frequency limits for Q5121. Exceeding published limits without documented medical necessity will result in denial.

Practices using practice management software with integrated eligibility verification reduce the administrative burden of tracking PA status across multiple payers. Centralising PA documentation alongside the clinical record also helps if a payer requests retrospective review. For practices that also handle complex diagnostic documentation workflows, see how diagnostic code documentation principles apply to supporting medical necessity cases.

Common denial reasons and how to avoid them

Biosimilar infusion claims are denied more often than most other outpatient drug claims because they combine drug coverage, procedure coverage, and medical necessity requirements in one submission. Knowing the common failure points prevents unnecessary write-offs.

• Wrong code submitted – billing J1745 (Remicade) when Avsola was dispensed. The NDC on the claim will contradict the HCPCS code, triggering an automatic edit.
• Missing or incomplete prior authorization – failing to obtain PA before administration, or submitting a PA for the wrong biosimilar product.
• Incorrect unit count – rounding errors in weight-based dose calculations result in overbilling (audit risk) or underbilling (revenue loss).
• Missing modifier – omitting the JA modifier on a Medicare claim for IV infusion.
• Insufficient medical necessity documentation – the clinical note does not document the approved indication, patient weight, dose calculation, or prior treatment history.
• Step therapy not documented – for commercial plans requiring prior biologic failure, the record must show the specific agent tried, duration of therapy, and reason for discontinuation.
• NDC not included – many payers require the National Drug Code (NDC) alongside Q5121. Omitting the NDC is a common claim-level rejection cause.

Practices that track denial patterns by code and payer can identify systemic problems faster than those reviewing denials individually. An infusion clinic EMR software that logs denial reasons by HCPCS code makes this analysis straightforward. The AAPC Codify HCPCS lookup and PGM Billing’s HCPCS lookup tool are useful references for verifying code properties and modifier requirements during claim setup.

Conclusion

Getting HCPCS Code Q5121 right requires more than knowing the code number. Accurate unit calculation, correct modifier assignment, payer-specific prior authorization, and complete medical necessity documentation all have to align on the same claim. One misaligned element triggers a denial that costs more to remediate than it would have cost to prevent.

Pabau’s claims management software helps infusion and rheumatology practices build Q5121 billing workflows that check NDC codes, flag modifier gaps, and maintain the documentation trail payers require. To see how it works in your setting, book a demo with the team.

Continue your research

Need a structured workflow for your infusion documentation? Managing medical forms at your healthcare practice walks through how to build audit-ready documentation for physician-administered drugs.

Running a multi-payer infusion practice? HIPAA compliance for medical offices covers the record-keeping requirements that protect your practice during payer audits.

Want to compare biosimilar billing approaches across specialties? IVF CPT codes shows how procedure-level billing maps across a different specialty’s coding landscape.

Frequently Asked Questions